Matches in SemOpenAlex for { <https://semopenalex.org/work/W3112232017> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W3112232017 abstract "Abstract Background The goal is to assess the safety, tolerability, and pharmacokinetics of nilotinib, and measure biomarkers in participants with mild to moderate dementia due to Alzheimer’s disease. We hypothesized that nilotinib is safe and detectable in cerebrospinal fluid. Nilotinib may alter disease biomarkers and potentially slow clinical decline. Method This is a single‐center, phase 2, randomized, double‐blind, placebo‐controlled study. Of 117 individuals approached, 13 declined, 51 were excluded, 51 were screened, and 37 were randomized 1:1 to placebo or nilotinib groups. The Alzheimer’s disease diagnosis was supported by cerebrospinal fluid or amyloid positron emission tomography biomarkers. Nilotinib 150 mg vs matching placebo was taken orally once daily for 26 weeks followed by nilotinib 300 mg vs placebo for another 26 weeks. Result Of the 37 individuals enrolled, 27 were women (73%), and the mean (SD) age was 70.7 (6.48) years. Nilotinib was safe and well‐tolerated, although more adverse events, particularly mood swings, were noted at the 300 mg dose (70.6%) vs placebo (0%) groups (p<.01). In the nilotinib group, amyloid burden was reduced in the temporal (‐0.08, 90% CI, ‐0.21 to ‐0.01, p=.04) and frontal lobes (‐0.19, 90% CI, ‐2.29 to ‐0.08, p<.001) compared to the placebo group. Cerebrospinal fluid Aβ40 was reduced at 6 months (566ng/ml, 90% CI, 135 to 1018, p=.02) and Aβ42 was reduced at 12 months (73.9 ng/ml, 90% CI, 14.3 to 137.9, p=.02) in the nilotinib group compared to the placebo. Hippocampal volume loss was attenuated (‐27%) at 12 months and phospho‐tau181 was reduced at 6 months (‐31.6%) and 12 months (‐39.6%) in the nilotinib group. Conclusion Nilotinib is safe and well‐tolerated, and achieves pharmacologically relevant brain concentrations. Biomarkers of Alzheimer's disease were altered in response to nilotinib treatment. These data support a larger, multi‐center, phase 3 study to determine the safety and efficacy of nilotinib in Alzheimer’s disease. ClinicalTrials.gov NCT02947893." @default.
- W3112232017 created "2020-12-21" @default.
- W3112232017 creator A5009146393 @default.
- W3112232017 creator A5010233603 @default.
- W3112232017 creator A5017067396 @default.
- W3112232017 creator A5018047271 @default.
- W3112232017 creator A5031622889 @default.
- W3112232017 creator A5045819980 @default.
- W3112232017 creator A5046518155 @default.
- W3112232017 creator A5048087226 @default.
- W3112232017 creator A5059916599 @default.
- W3112232017 creator A5061427734 @default.
- W3112232017 creator A5066883241 @default.
- W3112232017 creator A5070706767 @default.
- W3112232017 creator A5074186966 @default.
- W3112232017 creator A5074409890 @default.
- W3112232017 creator A5075158659 @default.
- W3112232017 creator A5087911213 @default.
- W3112232017 creator A5090295550 @default.
- W3112232017 creator A5090941234 @default.
- W3112232017 date "2020-12-01" @default.
- W3112232017 modified "2023-09-26" @default.
- W3112232017 title "Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer’s disease: A phase 2, double‐blind, randomized, placebo‐controlled trial" @default.
- W3112232017 doi "https://doi.org/10.1002/alz.044628" @default.
- W3112232017 hasPublicationYear "2020" @default.
- W3112232017 type Work @default.
- W3112232017 sameAs 3112232017 @default.
- W3112232017 citedByCount "0" @default.
- W3112232017 crossrefType "journal-article" @default.
- W3112232017 hasAuthorship W3112232017A5009146393 @default.
- W3112232017 hasAuthorship W3112232017A5010233603 @default.
- W3112232017 hasAuthorship W3112232017A5017067396 @default.
- W3112232017 hasAuthorship W3112232017A5018047271 @default.
- W3112232017 hasAuthorship W3112232017A5031622889 @default.
- W3112232017 hasAuthorship W3112232017A5045819980 @default.
- W3112232017 hasAuthorship W3112232017A5046518155 @default.
- W3112232017 hasAuthorship W3112232017A5048087226 @default.
- W3112232017 hasAuthorship W3112232017A5059916599 @default.
- W3112232017 hasAuthorship W3112232017A5061427734 @default.
- W3112232017 hasAuthorship W3112232017A5066883241 @default.
- W3112232017 hasAuthorship W3112232017A5070706767 @default.
- W3112232017 hasAuthorship W3112232017A5074186966 @default.
- W3112232017 hasAuthorship W3112232017A5074409890 @default.
- W3112232017 hasAuthorship W3112232017A5075158659 @default.
- W3112232017 hasAuthorship W3112232017A5087911213 @default.
- W3112232017 hasAuthorship W3112232017A5090295550 @default.
- W3112232017 hasAuthorship W3112232017A5090941234 @default.
- W3112232017 hasBestOaLocation W31122320171 @default.
- W3112232017 hasConcept C126322002 @default.
- W3112232017 hasConcept C142724271 @default.
- W3112232017 hasConcept C168563851 @default.
- W3112232017 hasConcept C170493617 @default.
- W3112232017 hasConcept C197934379 @default.
- W3112232017 hasConcept C204787440 @default.
- W3112232017 hasConcept C27081682 @default.
- W3112232017 hasConcept C2777413986 @default.
- W3112232017 hasConcept C2778375690 @default.
- W3112232017 hasConcept C42362537 @default.
- W3112232017 hasConcept C71924100 @default.
- W3112232017 hasConcept C90924648 @default.
- W3112232017 hasConceptScore W3112232017C126322002 @default.
- W3112232017 hasConceptScore W3112232017C142724271 @default.
- W3112232017 hasConceptScore W3112232017C168563851 @default.
- W3112232017 hasConceptScore W3112232017C170493617 @default.
- W3112232017 hasConceptScore W3112232017C197934379 @default.
- W3112232017 hasConceptScore W3112232017C204787440 @default.
- W3112232017 hasConceptScore W3112232017C27081682 @default.
- W3112232017 hasConceptScore W3112232017C2777413986 @default.
- W3112232017 hasConceptScore W3112232017C2778375690 @default.
- W3112232017 hasConceptScore W3112232017C42362537 @default.
- W3112232017 hasConceptScore W3112232017C71924100 @default.
- W3112232017 hasConceptScore W3112232017C90924648 @default.
- W3112232017 hasIssue "S9" @default.
- W3112232017 hasLocation W31122320171 @default.
- W3112232017 hasOpenAccess W3112232017 @default.
- W3112232017 hasPrimaryLocation W31122320171 @default.
- W3112232017 hasRelatedWork W1966047811 @default.
- W3112232017 hasRelatedWork W2003042623 @default.
- W3112232017 hasRelatedWork W202460821 @default.
- W3112232017 hasRelatedWork W2035049801 @default.
- W3112232017 hasRelatedWork W2068849886 @default.
- W3112232017 hasRelatedWork W2109235243 @default.
- W3112232017 hasRelatedWork W2147606462 @default.
- W3112232017 hasRelatedWork W3023502736 @default.
- W3112232017 hasRelatedWork W3139841107 @default.
- W3112232017 hasRelatedWork W4308071420 @default.
- W3112232017 hasVolume "16" @default.
- W3112232017 isParatext "false" @default.
- W3112232017 isRetracted "false" @default.
- W3112232017 magId "3112232017" @default.
- W3112232017 workType "article" @default.